-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Huiyu Pharmaceutical entered the administrative examination and approval stage with the imitation of bendamustine hydrochloride for injection, which was reported for production in the 3rd category.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
Bendamustine hydrochloride is a bifunctional alkylating agent used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Pending approval of bendamustine hydrochloride for injection
At present, there are 3 approved enterprises of bendamustine hydrochloride for injection in the domestic market, including Cephalon, Chia Tai Tianqing Pharmaceutical Group and Jianjin Pharmaceutical.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Huiyu Pharmaceutical passed the consistency evaluation of the injection
Source: Mi Nei Net Consistency Evaluation Database
As the focus on high-end anti-tumor injections of business , Huiyu has five pharmaceutical anti -tumor injections over assessment, including injection pemetrexed disodium, docetaxel injection, azacitidine for injection, and paclitaxel injection Oxaliplatin injection.
Bendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Bendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Source: Mi Neiwang database, NMPA
Recently, Huiyu Pharmaceutical entered the administrative examination and approval stage with the imitation of bendamustine hydrochloride for injection, which was reported for production in the 3rd category.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
Bendamustine hydrochloride is a bifunctional alkylating agent used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Pending approval of bendamustine hydrochloride for injection
At present, there are 3 approved enterprises of bendamustine hydrochloride for injection in the domestic market, including Cephalon, Chia Tai Tianqing Pharmaceutical Group and Jianjin Pharmaceutical.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Huiyu Pharmaceutical passed the consistency evaluation of the injection
Source: Mi Nei Net Consistency Evaluation Database
As the focus on high-end anti-tumor injections of business , Huiyu has five pharmaceutical anti -tumor injections over assessment, including injection pemetrexed disodium, docetaxel injection, azacitidine for injection, and paclitaxel injection Oxaliplatin injection.
Bendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Bendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Source: Mi Neiwang database, NMPA
Recently, Huiyu Pharmaceutical entered the administrative examination and approval stage with the imitation of bendamustine hydrochloride for injection, which was reported for production in the 3rd category.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
It is expected to be approved in the near future and become the third domestic manufacturer.
According to data from Meinenet, the highest global sales of bendamustine hydrochloride for injection were US$767 million in 2014 and US$496 million in 2019.
Bendamustine hydrochloride is a bifunctional alkylating agent used in the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Bendamustine hydrochloride for injection was developed by Cephalon under the trade name Treanda.
It was approved for marketing in the United States in March 2008 and approved for marketing in China in December 2018.
In May 2011, Teva acquired Treanda for US$6.
8 billion.
According to data from Meinenet, Teva's global sales of bendamustine hydrochloride for injection were the highest in 2014 at US$767 million, and sales in 2019 were US$496 million.
Pending approval of bendamustine hydrochloride for injection
At present, there are 3 approved enterprises of bendamustine hydrochloride for injection in the domestic market, including Cephalon, Chia Tai Tianqing Pharmaceutical Group and Jianjin Pharmaceutical.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Simcere Pharmaceuticals and Yangtze River Pharmaceutical Group's applications for bendamustine hydrochloride for injection are under review and approval.
Huiyu Pharmaceutical's registration status of bendamustine hydrochloride for injection has been changed to "under approval", and if it is successfully approved, it will become the third domestic company.
Huiyu Pharmaceutical passed the consistency evaluation of the injection
Source: Mi Nei Net Consistency Evaluation Database
As the focus on high-end anti-tumor injections of business , Huiyu has five pharmaceutical anti -tumor injections over assessment, including injection pemetrexed disodium, docetaxel injection, azacitidine for injection, and paclitaxel injection Oxaliplatin injection.
Bendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Corporate Corporate Corporate Tumor Tumor TumorBendamustine hydrochloride for injection is expected to become the 6th approved anti-tumor injection of Huiyu Pharmaceutical.
Source: Mi Neiwang database, NMPA
